Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Travis Costa"'
Autor:
Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan C. Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, Paul Gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps
Publikováno v:
Pharmacological Research, Vol 199, Iss , Pp 107048- (2024)
High baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients. Mechanisms linking ICI clearance, cachexia and ICI therapy failure are unknown
Externí odkaz:
https://doaj.org/article/2e67e650671f4d189b77c2eafc481db4
Autor:
Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva, Min Chen, Zhiliang Xie, Justin Thomas, Bryan Remaily, Yizhen Guo, Uma L. Subrayan, Travis Costa, Timothy H. Helms, Donald J. Irby, Kyeongmin Kim, Dwight H. Owen, Samuel K. Kulp, Thomas A. Mace, Mitch A. Phelps, Christopher C. Coss
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Abstract Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are
Externí odkaz:
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
Autor:
Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, paul gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9935f7885e84c4fb99ccbd5a6769edb3
https://doi.org/10.2139/ssrn.4423641
https://doi.org/10.2139/ssrn.4423641
Autor:
Thomas A. Mace, Samuel K. Kulp, Yizhen Guo, Sophia G. Liva, Trang Vu, Alyssa Marie M Castillo, Uma L Subrayan, Justin Thomas, Timothy H. Helms, Min Chen, Kyeongmin Kim, Zhiliang Xie, Christopher C. Coss, Travis Costa, Bryan Remaily, Mitch A. Phelps, Donald J. Irby, Dwight H. Owen
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Jcsm Rapid Communications
Jcsm Rapid Communications
Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5e047c2fd7517629863afea5696c35
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7